Technical Analysis for HOOK - HOOKIPA Pharma Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Up |
| See historical HOOK trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | -1.19% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | -1.19% | |
| Pocket Pivot | Bullish Swing Setup | -1.19% | |
| Wide Range Bar | Range Expansion | -1.19% | |
| Above Upper BB | Strength | -1.19% | |
| Up 3 Days in a Row | Strength | -1.19% | |
| Upper Bollinger Band Touch | Strength | -1.19% | |
| Crossed Above 20 DMA | Bullish | 7.25% | |
| Crossed Above 50 DMA | Bullish | 7.25% | |
| MACD Bullish Signal Line Cross | Bullish | 7.25% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Cancers Transplantation Gilead Sciences Immunotherapeutics Viral Disease
Biotechnology Biopharmaceutical Cancer Life Sciences Infectious Diseases Cancers Transplantation Gilead Sciences Immunotherapeutics Viral Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more HOOK news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 14.76 |
| 52 Week Low | 6.06 |
| Average Volume | 25,819 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 7.5292 |
| 20-Day Moving Average | 7.321 |
| 10-Day Moving Average | 7.056 |
| Average True Range | 0.471 |
| ADX | 17.71 |
| +DI | 37.7436 |
| -DI | 17.2837 |
| Chandelier Exit (Long, 3 ATRs ) | 7.036999999999999 |
| Chandelier Exit (Short, 3 ATRs ) | 7.913 |
| Upper Bollinger Band | 8.38 |
| Lower Bollinger Band | 6.262 |
| Percent B (%b) | 1.0 |
| BandWidth | 28.930474 |
| MACD Line | -0.0659 |
| MACD Signal Line | -0.1737 |
| MACD Histogram | 0.1077 |
| Fundamentals | Value |
|---|---|
| Market Cap | 157.98 Million |
| Num Shares | 18.9 Million |
| EPS | 0.47 |
| Price-to-Earnings (P/E) Ratio | 17.94 |
| Price-to-Sales | 0.84 |
| Price-to-Book | 1.17 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.81 | ||||
| Resistance 3 (R3) | 9.67 | 9.06 | 9.57 | ||
| Resistance 2 (R2) | 9.06 | 8.70 | 9.13 | 9.49 | |
| Resistance 1 (R1) | 8.72 | 8.47 | 8.89 | 8.86 | 9.41 |
| Pivot Point | 8.11 | 8.11 | 8.20 | 8.18 | 8.11 |
| Support 1 (S1) | 7.77 | 7.75 | 7.94 | 7.91 | 7.35 |
| Support 2 (S2) | 7.16 | 7.52 | 7.23 | 7.27 | |
| Support 3 (S3) | 6.82 | 7.16 | 7.19 | ||
| Support 4 (S4) | 6.96 |
